RECRUITING

Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy

Talk to us

Conditions

Critical Asymptomatic Carotid Artery DiseaseNon-Critical Asymptomatic Carotid Artery Disease

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical imaging substudy will use the small molecule translocator protein (TSPO) ligand, Fludeoxyglucose(18F)-labeled DPA-714, to compare neuroinflammation in individuals with high or low grade asymptomatic carotid artery stenosis (aCAD) who are participating in the separate Neuroinflammation in Asymptomatic Carotid Artery Disease study lead by Dr. Ron Lazar (IRB-300007806). The positron emission tomography (PET) tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation.

Official Title

Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy

Quick Facts

Study Start:2025-04-01
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05238961

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. 1. Contraindication to MRI
  2. 2. Pregnancy or lactation
  3. 3. Previous revascularization for treatment of aCAD
  4. 4. Prior stroke
  5. 5. Severe anemia (blood hemoglobin ≤ 8 mg/dL)
  6. 6. Previously obtained MRI scan with evidence of clinically significant abnormality
  7. 7. History of traumatic head injury defined by loss of consciousness \>30 minutes or seizure at the time of the injury
  8. 8. Major depression
  9. 9. Known history of dementia
  10. 10. Serious medical comorbidity that, based on the judgement of the principal investigator, may interfere with study participation
  11. 11. Low or mixed-affinity binding for TSPO ligands based on genotyping for SNP rs6971.

Contacts and Locations

Study Contact

Evan Hudson
CONTACT
205-934-6499
evanhudson@uabmc.edu

Principal Investigator

Jonathan McConathy, MD,PhD
PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham

Study Locations (Sites)

UAB
Birmingham, Alabama, 35294
United States

Collaborators and Investigators

Sponsor: University of Alabama at Birmingham

  • Jonathan McConathy, MD,PhD, PRINCIPAL_INVESTIGATOR, University of Alabama at Birmingham

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-04-01
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2025-04-01
Study Completion Date2026-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Critical Asymptomatic Carotid Artery Disease
  • Non-Critical Asymptomatic Carotid Artery Disease